<DOC>
	<DOCNO>NCT02821390</DOCNO>
	<brief_summary>The analgesic effect Nepafenac 0.1 % Ophthalmic Drops ocular pain related intravitreal injection evaluate . Pain perception assess Short Form McGill Pain Questionnaire .</brief_summary>
	<brief_title>Effect Topical Nepafenac 0.1 % Pain Related Intravitreal Injections</brief_title>
	<detailed_description>Intravitreal injection ( IVI ) prefer route administration drug posterior segment eye . Intravitreal injection anti-VEGFs constitutes mainstay treatment various retinal disease AMD , RVO , DME etc . The procedure IVI , however , associate level discomfort patient . Ophthalmic nonsteroidal anti-inflammatory drug ( NSAIDs ) constitute establish effective treatment option management inflammation pain associate cataract surgery pain associate corneal refractive surgery , inhibition intraoperative miosis treatment seasonal allergic conjunctivitis . The primary goal study assess analgesic effect Nepafenac 0.1 % Eye Drops topical NSAID pain related intravitreal injection immediately six hour post-IVI . A number patient schedule undergo IVIs divide two group . All patient must already undergo least one IVI . In patient receive IVIs eye one eye include study . The patient first group randomize receive Nepafenac 0.1 % Eye Drops first appointment crossover receive placebo ( Artificial Tears ) next appointment IVI . The patient second randomized receive placebo ( Artificial Tears ) first appointment crossover receive Nepafenac 0.1 % Eye Drops next appointment IVI . All drug administer prior injection member Department 's personnel ( staff nurse ) . Patients require complete greek version short form McGill Pain Questionnaire ( SF-MPQ ) comprise Visual Analogue Scale , main component SF-MPQ Present Pain Intensity Scale immediately injection 6 hour post-IVI .</detailed_description>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<criteria>All participant patient Medical Retina Department Clinic , schedule receive IVIs ranibizumab ( Lucentis ; Novartis Pharma S.A.S. , Huningue , France ) aflibercept ( Eylea ; Bayer Healthcare Pharmaceuticals , Berlin , Germany ) one eye already undergone least one IVI antiVEGF agent . History previous eye surgery cataract extraction surgery , herpetic eye disease , uncontrolled glaucoma , uveitis , active conjunctivitis , keratitis bullous keratopathy , previously know allergic response bromfenac NSAIDs salicylates , systemic topical use NSAIDs use sedative medication within 7 day visit day IVI . Patients poor cooperation understand answer question SFMPQ , include visual analogue scale ( VAS ) . Unsuccessful blinding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>intravitreal injection</keyword>
	<keyword>pain</keyword>
	<keyword>non-steroidal anti-inflammatory drug</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>nepafenac</keyword>
</DOC>